PART I . Overview We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Our lead program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. In addition, RLYB332, a long-acting matriptase-2 ("M...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001628280-26-018261 | EDGAR | 108K words |
| 2025-03-13 | 2024-12-31 | 0001739410-25-000040 | EDGAR | — |
| 2024-03-12 | 2023-12-31 | 0001739410-24-000035 | EDGAR | — |
| 2023-03-06 | 2022-12-31 | 0000950170-23-006264 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0000950170-22-003767 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001739410-25-000132 | EDGAR | 54K words |
| 2025-08-07 | 2025-06-30 | 0001739410-25-000112 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001739410-25-000061 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001739410-24-000136 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001739410-24-000115 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001739410-24-000057 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001739410-23-000014 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001739410-23-000007 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019165 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022342 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015571 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-009013 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001628280-26-022385 | EDGAR | 1K words |
| 2026-03-02 | 0001193125-26-084444 | EDGAR | — |
| 2026-01-29 | 0001739410-26-000010 | EDGAR | — |
| 2025-11-06 | 0001739410-25-000131 | EDGAR | — |
| 2025-08-29 | 0001193125-25-192749 | EDGAR | — |
| 2025-08-07 | 0001739410-25-000108 | EDGAR | — |
| 2025-07-08 | 0001739410-25-000100 | EDGAR | — |
| 2025-06-27 | 0001739410-25-000093 | EDGAR | — |
| 2025-05-16 | 0001739410-25-000089 | EDGAR | — |
| 2025-05-08 | 0001739410-25-000059 | EDGAR | — |
79 total filings indexed. 52 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001739410 |
| Ticker | RLYB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.rallybio.com |
| Listed | 2021-07-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report